The systemic exposure at these levels is approximately equivalent to or less than 0.5 times the clinical exposure at the recommended clinical dose of 2 g/ day for renal transplant patients and approximately 0.3 times the clinical exposure at the recommended clinical dose of 3 g/ day for cardiac transplant patients.
Toimeaine süsteemne sisaldus selliste annuste kasutamisel on neerutransplantaadiga patsientidel (päevaannus 2 g) ≤0, 5 korda ja südametransplantaadiga patsientidel (päevaannus 3 g) umbes 0, 3 korda suurem kliiniliselt efektiivsest süsteemsest toimeaine sisaldusest.